Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(4 years from now) | |
US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(5 years from now) | |
US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(4 years from now) | |
US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(4 years from now) | |
US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 3, 2026 |
Orphan Drug Exclusivity (ODE) | Feb 3, 2028 |
NCE-1 date: 2025-02-03
Market Authorisation Date: 03 February, 2021
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...
Dosage: TABLET;ORAL